Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Odile Launay

Showing results (231-240 of 305) with videos related to

Pageof 31
Sort By:
Clinical and Vaccine Immunology : CVI|December 28, 2013
Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008-2009 vaccine efficacy trialSerge Durviaux, John Treanor, Jiri Beran, et al.
The Journal of Infectious Diseases|June 2, 2011
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trialOdile Launay, Corinne Desaint, Christine Durier, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 13, 2021
Severity of self-reported symptoms and psychological burden 6-months after hospital admission for COVID-19: a prospective cohort studyPhilippine Eloy, Coralie Tardivon, Guillaume Martin-Blondel, et al.
Nature Communications|November 5, 2025
Safety and immunogenicity of PPV-06, an active anti-IL-6 immunotherapy targeting low-grade inflammation against knee osteoarthritis: a randomized, double-blind, placebo-controlled, clinical phase 1 studyFrançois Rannou, Lucille Desallais, Christelle Nguyen, et al.
Vaccine|May 21, 2026
Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC studyBrigitte Ranque, Florence Galtier, Hilario Nunes, et al.
Blood|July 18, 2012
Pivotal role of M-DC8⁺ monocytes from viremic HIV-infected patients in TNFα overproduction in response to microbial productsCharles-Antoine Dutertre, Sonia Amraoui, Annalisa DeRosa, et al.
Plos One|August 23, 2007
Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trialOdile Launay, Christine Durier, Corinne Desaint, et al.
Ebiomedicine|July 25, 2017
Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in EuropeOdile Launay, David J M Lewis, Alessandra Anemona, et al.
Expert Review of Vaccines|October 20, 2022
The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiativeJavier Díez-Domingo, Laurence Torcel-Pagnon, Antonio Carmona, et al.
Eclinicalmedicine|December 9, 2024
Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)Yves Levy, Christiane Moog, Aurélie Wiedemann, et al.
Pageof 31

Showing results (231-240 of 305) with videos related to

Sort By:
Pageof 31
Clinical and Vaccine Immunology : CVI|December 28, 2013
Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008-2009 vaccine efficacy trialSerge Durviaux, John Treanor, Jiri Beran, et al.
The Journal of Infectious Diseases|June 2, 2011
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trialOdile Launay, Corinne Desaint, Christine Durier, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 13, 2021
Severity of self-reported symptoms and psychological burden 6-months after hospital admission for COVID-19: a prospective cohort studyPhilippine Eloy, Coralie Tardivon, Guillaume Martin-Blondel, et al.
Nature Communications|November 5, 2025
Safety and immunogenicity of PPV-06, an active anti-IL-6 immunotherapy targeting low-grade inflammation against knee osteoarthritis: a randomized, double-blind, placebo-controlled, clinical phase 1 studyFrançois Rannou, Lucille Desallais, Christelle Nguyen, et al.
Vaccine|May 21, 2026
Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC studyBrigitte Ranque, Florence Galtier, Hilario Nunes, et al.
Blood|July 18, 2012
Pivotal role of M-DC8⁺ monocytes from viremic HIV-infected patients in TNFα overproduction in response to microbial productsCharles-Antoine Dutertre, Sonia Amraoui, Annalisa DeRosa, et al.
Plos One|August 23, 2007
Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trialOdile Launay, Christine Durier, Corinne Desaint, et al.
Ebiomedicine|July 25, 2017
Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in EuropeOdile Launay, David J M Lewis, Alessandra Anemona, et al.
Expert Review of Vaccines|October 20, 2022
The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiativeJavier Díez-Domingo, Laurence Torcel-Pagnon, Antonio Carmona, et al.
Eclinicalmedicine|December 9, 2024
Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)Yves Levy, Christiane Moog, Aurélie Wiedemann, et al.
Pageof 31